ABOS News and Press, Acumen Pharmaceuticals Inc. From 11/13/23

Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? PR Newswire NEW YORK , Nov. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TIVC, TYGO, TATT, PSTV, ...

2023-11-13 07:10:00 ET More on Acumen Pharmaceuticals Navigating Acumen's Alzheimer's Risk And Reward Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data Halozyme, Acumen enter collaboration for Alzheimer's drug candidate Seeking Alpha...

Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes $30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen ...

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 Announced global collaboration and license agreement with Halozyme for development...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Acumen Pharmaceuticals Inc. (ABOS) is expected to report $-0.31 for Q3 2023

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta ...

2023-11-06 08:23:39 ET More on Acumen Pharmaceuticals, Halozyme Therapeutics, etc. Navigating Acumen's Alzheimer's Risk And Reward Acumen Pharmaceuticals: Novel Alzheimer's Molecule With Positive Early Data Halozyme: Intriguing Buy Prospect Despite This Week's PDUFA ...

CHARLOTTESVILLE, Va., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today tha...

- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to inform dose selection, plus further analyses of dose-related amyloid plaque reduction and clinical characteristics of ARIA-E, confirming proof...